Investigational drug · Phase 2
CRD-4730
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Catecholaminergic Polymorphic Ventricular Tachycardia, Heart Failure With Reduced Ejection Fraction (HFrEF).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "CRD-4730"
First trial start
2025
Dec 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CRD-4730", any sponsor or status.
Conditions studied
As listed on its trial records.
- Catecholaminergic Polymorphic Ventricular Tachycardia
- Heart Failure With Reduced Ejection Fraction (HFrEF)
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CRD-4730" as an intervention, largest first.
- A Trial of CRD-4730 in HFrEFPivotal-lookingRecruiting
Cardurion Pharmaceuticals, Inc.Industry
NCT07750873 · 525 participants (planned) · Start Jul 15, 2026 · Primary completion Sep 2028
Drug: CRD-4730; Placebo · For: Heart Failure With Reduced Ejection Fraction (HFrEF)
Sites: Pasadena, California; Bloomfield Hills, Michigan
- A Phase 2 Study of CRD-4730 in CPVTRecruiting
Cardurion Pharmaceuticals, Inc.Industry
NCT06658899 · 12 participants (planned) · Start Dec 1, 2025 · Primary completion Apr 2027
Drug: CRD-4730; Placebo · For: Catecholaminergic Polymorphic Ventricular Tachycardia
Sites: San Francisco, California; Morrisville, North Carolina; Houston, Texas · 12 sites in all
Cardurion Pharmaceuticals, Inc.Industry
NCT06005428 · 7 participants · Start Nov 7, 2023 · Primary completion May 31, 2025
Drug: CRD-4730; Placebo · For: CPVT1; Heart Defects, Congenital; Heart Diseases and 1 more
Sites: Cincinnati, Ohio; Cleveland, Ohio; Houston, Texas · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Catecholaminergic Polymorphic Ventricular Tachycardia
- AGP100Phase 21 trial
Agiana Pharmaceuticals · Catecholaminergic Polymorphic Ventricular Tachycardia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.